LINK INDEX PARAMETERS

Modification Reference Values

Test code: 3190

PREVIOUS Reference Values	CURRENT Reference Values
IgG C.S.F       = 0.36 - 3.40 mg/dL   ALBUMIN Serum   = 33 - 52      g/L   IgG Serum       = 290 - 1600  mg/dL   ALBUMIN C.S.F.  = 15 - 30     mg/dL   INDEX:          = 0.34 - 0.58	IgG C.S.F       = 0.36 - 3.40 mg/dL   ALBUMIN Serum   = 33 - 52      g/L   IgG Serum       = 290 - 1600  mg/dL   ALBUMIN C.S.F.  = 15 - 30     mg/dL   INDEX:          = Less than 0.85

   Find the record of the test by clicking here

MYELIN BASIC PROTEIN , CSF

Erased test in CIC Catalog

Test Code: 2004

Discontinued for technical reasons (commercial reagents not available) and decrease in demand.

FLECAINIDA [APOCARD] ®, SERUM

Modification Units and Reference values

Test code: 1426

PREVIOUS Units and Reference values	CURRENT  Units and Reference values
0.2 - 1.0 mg/L	Adults:                            300 - 800 µg/L Children:                         200 - 500 µg/L Potentially Toxic:  Greater than 1000 µg/L Toxic:                 Greater than 1600 µg/L

   Find the record of the test by clicking here

MACROAMYLASE, SERUM

Erased test in CIC Catalog

Test Code: 3472

The test has been discontinued due to the absence of commercialised kits on the market. 

ANTI-SALIVARY GLAND ANTIBODIES, SERUM

Erased test in CIC Catalog

Test Code: 1423

The test has been discontinued due to its low specificity and lack of clinical interest for the diagnosis of Gougerot-Sjögren syndrome. The diagnostic criteria have been stablished by AECG (American European Consensus Group).

PROCOLLAGEN TYPE I N-TERMINAL PROPEPTIDE, SERUM

Modification Reference Values

Test code: 2650

PREVIOUS Reference Values	CURRENT Reference Values
Men:        21 -  78 µg/L Women: 19 - 102 µg/L	Pre-menopausal women:              15.1 - 58.6 µg/L                                               (Average: 30.10 µg/L) Post-menopausal women: -WITHOUT substitution treatment: 20.5 - 76.3 µg/L                                                  (Average: 45.1 µg/L)  - WITH substitution treatment:      14.3 - 58.9 µg/L                                                 (Average: 31.7 µg/L)

   Find the record of the test by clicking here

MOLECULAR STUDY ALEXANDER DISEASE (GFAP) SEQUENCING, WHOLE BLOOD

New Test in CIC Catalog

Test Code: 4009

Sample:	Whole blood - EDTA (5 ml)
Conservation:	Refrigerated
Method:	Sequencing Method
Set Up Days:	Daily
TAT (Days):	35 days
Information:
Alexander's disease, a neurodegenerative disorder, was identified in 1949 on the basis of neurohistological criteria, i.e., the presence of dystrophic astrocytes containing intermediate filament aggregates (Rosenthal fibers) associated with myelin abnormalities. Since then, different clinical forms have been individualized. The infantile form (birth to 2 years), the most common, is characterized by its early onset and severe evolution. Its symptomatology associates progressive megalencephaly (sometimes hydrocephaly), retarded psychomotor development or mental deterioration, pyramidal signs, ataxia and convulsive seizures. Computed tomography scan and magnetic resonance imaging suggest the diagnosis by revealing white matter anomalies, predominantly in the frontal lobes. Juvenile forms start in school-aged children and associate spastic paraplegia and progressive bulbar signs. Adult forms are heterogeneous and difficult to diagnose. This rare disease, often considered to be a leukodystrophy, is usually sporadic; only a few familial cases have been reported. The discovery of Rosenthal fibers in transgenic mice overexpressing human glial fibrillary acidic protein (GFAP), which is the main intermediate filament of astrocyte, led to the search for mutations in its encoding gene. More than 20 GFAP mutations have been reported; they are de novo dominant mutations. However, a prenatal diagnosis seems desirable in light of the risk of germinal/germ-cell mosaicism. At present, treatment is purely symptomatic.
Links:
OMIM Entry - #203450 - ALEXANDER DISEASE
Orphanet- Alexander disease
OMIM Entry - -137780 - GLIAL FIBRILLARY ACIDIC PROTEIN; GFAP

   Find the record of the test by clicking here

THALLIUM (CREATININE) , URINE

New Test in CIC Catalog

Test Code: 4006

Sample:	Urine (10 ml)
Conservation:	Refrigerated
Method:	Spectrophotometry Atomic Absorption (LOINC®: AAS)
Set Up Days:	Th,
TAT (Days):	5 days

   Find the record of the test by clicking here

THALLIUM, URINE

Modification Units and Reference values

Test code: 6054

PREVIOUS Units and Reference values	CURRENT  Units and Reference values
Less than 10 µg/g creatinine	Less than 50 µg/L

   Find the record of the test by clicking here

THALLIUM , SERUM

Modification Units and Reference values

Test code: 6010

PREVIOUS Units and Reference values	CURRENT  Units and Reference values
Less than 5 µg/L	Less than 1.0 µg/dL

   Find the record of the test by clicking here

PHENYLALANINE, SERUM/PLASMA

New Test in CIC Catalog

Test Code: 4005

Sample:	Serum or Plasma (EDTA,Heparine Litium) (1mL)
Conservation:	Refrigerated
Method:	High Performance Liquid Chromatography (LOINC®: HPLC)
Set Up Days:	Daily
TAT (Days):	7 days

   Find the record of the test by clicking here

MOLECULAR STUDY - GLUCOGENESIS TYPE III (AGL) SEQUENCING, WHOLE BLOOD

New Test in CIC Catalog

Test Code: 4004

Sample:	Whole blood - EDTA (5 ml)
Conservation:	Refrigerated
Method:	Sequencing Method
Set Up Days:	Daily
TAT (Days):	50 days
Information:
GSD-III, which is also called Forbes disease and Cori disease, is caused by a deficiency of the glycogen disbranching enzyme. The lack of activity of this enzyme results in an incomplete breakdown of glycogen and glycogen accumulates. Clinically, GSD-III is characterized by hepatomegaly and hypoglycemia, and patients typically are short in stature. Additionally, most patients have disease involving both liver and muscle, which is termed type IIIa disease. However, in about 15% of the patients, GSD-III appears to involve only the liver, which is classified as type IIIb disease. Furthermore, during infancy and childhood, hepatomegaly, hypoglycemia, hyperlipidemia, and short stature are predominant features. The liver-related symptoms in most GSD-III patients improve with age and are usually resolved after puberty. In patients having muscular involvement, muscle weakness can occur, ranging in severity from not apparent or very minimal during early childhood to severe after the third or fourth decade of life. The patient's serum creatine kinase level can be used to determine muscle involvement; however, a normal level does not rule out the presence of muscle enzyme deficiency. Our laboratory offers complete sequencing of the AGL gene.
Links:
OMIM Entry - #232400 - GLYCOGEN STORAGE DISEASE III
Orphanet- Glycogen debranching enzyme deficiency
OMIM Entry - -610860 - AMYLO-1,6-GLUCOSIDASE, 4-ALPHA-GLUCANOTRANSFERASE; AGL

   Find the record of the test by clicking here

BETA CAROTENE, SERUM

New Test in CIC Catalog

Test Code: 4003

Sample:	Serum (1 ml)
Conservation:	Refrigerated
Method:	High Performance Liquid Chromatography (LOINC®: HPLC)
Set Up Days:	Daily
TAT (Days):	16 days

   Find the record of the test by clicking here

CARBOHYDRATES, URINE

New Test in CIC Catalog

Test Code: 4002

Sample:	Urine (10 ml)
Conservation:	Refrigerated
Method:	Spectrophotometry (LOINC®: S)
Set Up Days:	Daily
TAT (Days):	2 days

   Find the record of the test by clicking here

BREATH TEST - HYDROGEN FOR THE DETECTION OF LACTOSE INTOLERANCE

New Test in CIC Catalog

Test Code: 3999

Sample:	Special tube provided by CIC
Conservation:	Room temperature
Method:	Gas Chromatography/Mass Spectrometry (LOINC®: GC/MS)
Set Up Days:	Daily
TAT (Days):	4 days
Information:
Approximately half of our daily need of calories derived from carbohydrates. Most of these are ingested in the form of starch, which by salivary and pancreatic amylase is hydrolyzed and gives rise to oligosaccharides and then disaccharides (sucrose, maltose and lactose) and monosaccharides (glucose fructose and galactose). The latter are absorbed directly into the small intestinal epithelium without previous digestion. However, the disaccharides must be cleaved by enzymes previously found in the villous epithelial cells. An insufficient digestion or absorption of carbohydrates exposed them to a bacterial fermentation in the distal small intestine and colon. During fermentation originate short chain fatty acids and gases such as carbon dioxide (C02) and hydrogen (H2). These gases diffuse partially into the blood and are then exhaled. Because the body H2 is formed exclusively by bacterial fermentation of carbohydrates, the concentration of H2 in the exhaled air reflects the decomposition thereof in the intestine. Therefore, the determination of H2 can be used in the exhaled air to show an abnormal breakdown and poor absorption of carbohydrates. Fasting produces little or no H2 excretion through the lungs. However, the appearance of H2 with fasting can be relatively high if the intestine due to an insufficient fasting, it contains many carbohydrate residues. If a carbohydrate, after being administered is not completely absorbed increases the excretion of H2. However, if the absorption is insufficient, one part arrives at the colon and fermentation occurs with the consequent production of H2. In the case of bacterial overgrowth in the small intestine, the fermentation of carbohydrates can increase the excretion of H2 at 30-45 min after administration. This increase reflects the fermentation of the unabsorbed part of the carbohydrate. Thus, when using differents types of carbohydrates can be demonstrated alterations in the digestion and absorption of monosaccharides, disaccharides or polysaccharides. In an insufficient absorption of any carbohydrate is followed by production of H2, and consequently a positive breath hydrogen tests. In some individuals the bacteria colonizing the colon are not producing H2 and instead produce methane (CH4), so it is recommended that the joint determination of these two gases.

   Find the record of the test by clicking here

ACETOACETATE, URINE

New Test in CIC Catalog

Test Code: 1524

Sample:	Urine (10 ml)
Conservation:	Frozen
Method:	Spectrophotometry (LOINC®: S)
Set Up Days:	Daily
TAT (Days):	8 days

   Find the record of the test by clicking here

MOLECULAR STUDY GEN IDH1, TISSUE

New Test in CIC Catalog

Test Code: 3998

Sample:	Tumoral tissue
Conservation:	Room temperature
Method:	Sequencing Method
Set Up Days:	Daily
TAT (Days):	20 days

   Find the record of the test by clicking here

MOLECULAR STUDY GEN MGMT, TISSUE

New Test in CIC Catalog

Test Code: 3997

Sample:	Tumoral tissue
Conservation:	Room temperature
Method:	Sequencing Method
Set Up Days:	Daily
TAT (Days):	20 days

   Find the record of the test by clicking here

TOXIN A+B AND ANTIGEN OF CLOSTRIDIUM DIFFICILE (SIMULTANEOUS DETECTION), STOOL

New Test in CIC Catalog

Test Code: 3982

Sample:	Stool
Conservation:	Refrigerated
Method:	Enzyme Immunoassay (LOINC®: EIA)
Set Up Days:	Daily
TAT (Days):	1 days

   Find the record of the test by clicking here

HISTIDINE 3 METHYL, URINE

Modification Units and Reference values

Test code: 1104

PREVIOUS Units and Reference values	CURRENT  Units and Reference values
Units: µmol/L Not detected.	Units: µmol/mmol creat 8-75 µmol/mmol creat

   Find the record of the test by clicking here

METHANOL, URINE

Modification Delivery Time 

Test code: 2888

PREVIOUS Delivery Time	CURRENT  Delivery Time
Delivery time: 10 days	Delivery time: 3 days

   Find the record of the test by clicking here

TOTAL 2,5 HEXANODIONE, URINE

Modification Delivery Time and Reference values

Test code: 2772

PREVIOUS Delivery Time and Reference values	CURRENT  Delivery Time and Reference values
Delivery time: 5 days n-HEXANE           : B.E.I.(final shift) 5 mg/g creatinine METIL-n-BUTILCETONA: B.E.I.(final shift) 4 mg/L B.L.V.(final shift):          5 mg/g creatinine	Delivery time: 10 days B.L.V.(final shift) by I.N.S.H.T.:   n-HEXANE            : 0.4 mg/L (without acid hydrolysis) METIL-n-BUTILCETONE : 0.4 mg/L (without acid        hydrolysis)

   Find the record of the test by clicking here

METHANOL, WHOLE BLOOD

Modification Delivery Time and Reference values

Test code: 6020

PREVIOUS Delivery Time and Reference values	CURRENT  Delivery Time and Reference values
Delivery time: 10 days B.E.I.: 15 mg/L	Delivery time: 5 days Persons exposed: <500 mg/L

   Find the record of the test by clicking here

IgE SPECIFIC ANTIBODIES FOR ALFARE- NESTLE POWDERED MILK (f228)

Erased test in CIC Catalog

Test Code: 2464

The reagents for the tests outlined above are being permanently discontinued by the manufacturers as there is little demand and scientific interest for these analyses.

IgG1,IgG2,IgG3,IgG4 ( IgG SUBCLASS) , SERUM

Modification Reference Values

Test code: 1834

PREVIOUS Reference Values	CURRENT Reference Values
Adults              490-1140   150-640    20-110      8-140 (mg/dL)	Adults              405-1011   169-786    11-85      3-201 (mg/dL)

   Find the record of the test by clicking here

IgG4 ( IgG SUBCLASS 4) , SERUM

Modification Reference Values

Test code: 918

PREVIOUS Reference Values	CURRENT Reference Values
ADULTS:                  8 - 140 mg/dL	ADULTS:                  3 -  201 mg/dL

   Find the record of the test by clicking here